Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Maze Therapeutics, Inc. (MAZE) had Stock-Based Compensation of $16.40M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-131.12M |
|
-- |
|
-- |
|
$142.90M |
|
$-142.90M |
|
$11.78M |
|
$-131.12M |
|
$-131.12M |
|
$-131.12M |
|
$-131.12M |
|
$-131.12M |
|
$-131.12M |
|
$-142.90M |
|
$-140.50M |
|
42.98M |
|
42.98M |
|
$-3.05 |
|
$-3.05 |
|
| Balance Sheet Financials | |
$349.72M |
|
$5.04M |
|
$47.41M |
|
$397.13M |
|
$22.56M |
|
-- |
|
$19.61M |
|
$42.16M |
|
$354.97M |
|
$354.97M |
|
$354.97M |
|
49.34M |
|
| Cash Flow Statement Financials | |
$-111.94M |
|
$-170.96M |
|
$275.34M |
|
$197.90M |
|
$190.34M |
|
$-7.57M |
|
|
Stock-Based Compensation |
$16.40M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-112.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-36.94% |
|
-36.94% |
|
-33.02% |
|
-36.94% |
|
$7.19 |
|
$-2.62 |
|
$-2.60 |
|